絞り込み

17057

広告

The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.

著者 Tao X , Li N , Wu N , He J , Ying J , Gao S , Wang S , Wang J , Wang Z , Ling Y , Tang W , Zhang Z
Eur J Nucl Med Mol Imaging.2020 Feb 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Investigate whether F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy.
PMID: 32043180 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード